Equity Overview
Price & Market Data
Price: $0.435
Daily Change: +$0.052 / 11.95%
Range: $0.372 - $0.45
Market Cap: $27,354,838
Volume: 1,363,688
Performance Metrics
1 Week: 18.27%
1 Month: -3.90%
3 Months: -43.85%
6 Months: -6.42%
1 Year: -76.27%
YTD: -37.06%
Company Details
Employees: 28
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.